Fox Chase Cancer Center’s Dr. Joshua E. Meyer Named a Fellow of the American Society for Radiation Oncology

Meyer
Joshua E. Meyer, MD, FASTRO, Vice Chair of Translational Research and a Professor in the Department of Radiation Oncology at Fox Chase Cancer Center

PHILADELPHIA (September 28, 2025) — Joshua E. Meyer, MD, FASTRO, Vice Chair of Translational Research and a Professor in the Department of Radiation Oncology at Fox Chase Cancer Center, has been named a Fellow of the American Society for Radiation Oncology (ASTRO) at the organization’s 2025 Annual Meeting being held in San Francisco.

A Leader in Radiation Oncology

Fellowship in ASTRO is awarded to members who have made significant contributions to radiation oncology in the areas of research, clinical care, and service to the society.

Meyer, who joined Fox Chase in 2010, is a nationally recognized leader in radiation oncology and gastrointestinal cancer care and research. Board certified in radiation oncology, he has been repeatedly honored for both his clinical and academic contributions. He received the Association of Residents in Radiation Oncology Educator of the Year Award in 2015 and 2022, as well as the Paul Engstrom Award for Cancer Care Excellence in 2025.

Career Highlights

Meyer’s accomplishments reflect a career-long dedication to advancing cancer treatment:

  • Research & Career Honors: Recognized as an Outstanding Reviewer for the International Journal of Radiation Oncology, Biology, Physics, as well as one of Philadelphia magazine’s Top Doctors in 2023 and 2024.
  • Professional Development: Named Director of Clinical and Translational Research for the Gastrointestinal Service Line at Fox Chase as well as Director of the Marvin and Concetta Greenberg Pancreatic Cancer Institute.
  • Grants & Recognition: Awarded a grant from Varian Medical Systems, a Siemens Healthineers company, for studies on adaptive radiation use in rectal cancer. Additionally awarded the In Vino Vita Pilot Project Award for a study on locally advanced rectal cancer.

Active in Research and Professional Societies

At Fox Chase, Meyer is also a member of the Cancer Signaling and Microenvironment Research Program, where his work contributes to innovative approaches for improving patient outcomes. Beyond Fox Chase, he plays an active role in the professional community through his memberships in the American Society of Clinical Oncology, the American College of Radiology, and ASTRO, underscoring his leadership in shaping the field of radiation oncology at both the clinical and policy levels.

“It is an incredible honor to receive this recognition and stand alongside so many talented ASTRO members. Being part of this organization has been an amazing learning experience, and I am excited to continue this journey as a fellow,” said Meyer.

Shaping the Future of Radiation Oncology

Awards like ASTRO Fellowship recognize doctors who go above and beyond in patient care, research, and education. For patients, this means access to the latest treatments and clinical trials led by experts who are shaping the future of cancer care. For the medical community, fellows like Meyer mentor new doctors, help set treatment guidelines, and drive research that can improve outcomes for cancer patients everywhere.

This honor shows that a physician is not just exceptional in the clinic, but also a leader making a real difference in improving care and outcomes for people with cancer.

A Department of Excellence

“This is fantastic news and is well deserved. I am very excited for and proud of Josh. He is the sixth person in our department to be made an ASTRO Fellow. Considering that fewer than 500 physicians worldwide have been made ASTRO Fellows since 2006, Fox Chase has a high percentage based on our size,” said Eric M. Horwitz, MD, FABS, FASTRO, Professor and Chair, Department of Radiation Oncology at Fox Chase and the Lewis Katz School of Medicine at Temple University.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427

Resize Text